The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
After two failed studies, The Medicines Co.’s rapid-acting IV antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.